In:
International Journal of Cancer, Wiley, Vol. 144, No. 4 ( 2019-02-15), p. 886-896
Abstract:
What's new? Risk of cancer after solid organ transplantation is increased, in part due to immunosuppressive treatments modifying the balance between immune tolerance and anti‐tumoral immunity. mTOR inhibitors, which today are used either as an immunosuppressive agent to prevent graft rejection or an anti‐tumor drug, have shown therapeutic promise for these patients, however. In this large well‐documented cohort, immunosuppression dose reduction does not translate into overall survival benefit. Rather, optimal oncological treatment and introduction of a mTOR inhibitor at immunosuppressive doses are feasible without safety concerns in solid organ transplant patients presenting with de novo carcinoma, and dramatically improve patient overall survival.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink